Tag Archives: Biologics by McKesson

Biologics by McKesson and AllianceRx Expand Specialty Pharmacy Oncology Offerings

INQOVI is for the treatment of adults with intermediate and high-risk myelodysplastic syndromes (MDS) including chronic myelomonocytic leukemia (CMML), two blood malignancies

Biologics by McKesson Expands Specialty Pharmacy Oncology Offerings

Biologics, as part of a recent reorganization, is now joining McKesson’s Provider Solutions business within the Pharmaceutical Solutions and Services (PSaS) business unit

Immunomedics Chooses Biologics as Sole Specialty Pharmacy Distributor

Trodelvy is the first anti-Trop-2 ADC recently approved by the FDA for the treatment of adult patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease

Limited Distribution Network for DOPTELET® Includes Biologics by McKesson

Dova recently entered into a merger agreement with Swedish Orphan Biovitrum AB (Sobi)

Biologics to Play Leading Role in McKesson’s Strategy

McKesson Corporation announced a multi-year strategic growth initiative in 2018, focused on creating innovative new solutions that improve patient care delivery and drive incremental profit growth. The initiative comprises multiple growth pillars, and includes a comprehensive review of the company’s operations and cost structure, designed to increase efficiency, accelerate execution and improve long-term performance. McKesson’s […]